[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nafld-nonalcoholic-fatty-liver-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nafld-nonalcoholic-fatty-liver-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,77,101,136,167,192],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100632830","accurate-point-of-care-liver-disease-diagnostics-phase-2-100632830",false,"NCT07518784","Accurate Point of Care Liver Disease Diagnostics (Phase 2)","Accurate Point of Care Liver Disease Diagnostics","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Known or clinically suspected MASLD\n* BMI greater than 27 kg\u002Fm\\^2 and less than 45 kg\u002Fm\\^2 at the time of referral\n* Ability to lie on LiverScope® device table for about 60 minutes\n* Ability to hold breath repeatedly for about 20 seconds during MR and LiverScope® exams\n* Willing and able to undergo all study procedures\n\nExclusion Criteria:\n\n* UCSD study personnel or Livivos study personne\n* Contraindications to MR\n* Potential participant states that she knows that she is pregnant, thinks she may be pregnant, or states that she is trying to become pregnant.\n* Known chronic liver disease other than MASLD","ALL","18 Years",{"count":19,"type":20},26,"ESTIMATED","OBSERVATIONAL","This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. This is the second phase of a project in which we are testing a new technology to evaluate the liver (LiverScope®). We will compare LiverScope® to other methods to evaluate the liver, including advanced conventional liver MR exams. MR exams are common exams used to monitor MASLD (also known as NAFLD). Conventional MR scanners use magnetic fields and radio waves to make pictures of the liver. LiverScope® is a small, portable MR-based device that uses similar, but simplified technology, and can be used on top of an exam table in an outpatient setting. LiverScope® currently is not approved for clinical use.\n\nIn this second phase of the study, we took what we learned in the first phase to optimize the LiverScope® device and are now testing to see how LiverScope® measurements compare to MR after these optimizations.\n\nStudy participants will be asked to complete a one-time visit which includes:\n\n* LiverScope exam\n* MR exam\n* FibroScan exam (optional)\n* Blood draw\n* Completion of study questionnaires",[24,25,26,27],"MASLD","MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)","NAFLD","NAFLD (Nonalcoholic Fatty Liver Disease)","RECRUITING","2026-04-01",{"date":31,"type":32},"2026-04-09","ACTUAL",{"date":34,"type":20},"2026-04-08",{"date":36,"type":20},"2026-06-30",{"name":38,"class":39},"University of California, San Diego","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":40},"100570332","chrononutrition-chronotoxicity-intervention-in-people-with-metabolic-associated-steatotic-liver-disease-100570332","NCT06705868","Chrononutrition\u002F Chronotoxicity Intervention in People With Metabolic-associated Steatotic Liver Disease.","Time-restricted Eating in Patients With Metabolic-associated Steatotic Liver Disease . CHRONOMASLD: A Chrononutrition\u002FChronotoxicity Randomized Controlled Trial.","CHRONOMASLD","Inclusion Criteria:\n\n1. Body mass index 25 (±0,5)-45(±0,5) kg\u002Fm2\n2. Clinical diagnosis of MASLD, not excluding undiagnosed NASH or with NASH stage F0-F1\n3. Self-reported habitual eating period more than or equal to 14 h per day, BUT NOT LESS.\n4. Cyprus inhabitants of for at least 1 year\n5. Registered to the National Health System of the Republic of Cyprus (Gesy\n\nExclusion Criteria:\n\n1. Night Shift worker\n2. Fasting \\>12-h\u002Fday more than once a week or \\> once a week no food intake after 18:00\n3. Co-existing causes of chronic liver disease according to standard diagnostic testing including, but not restricted to:\n\n   1. Positive hepatitis B surface antigen\n   2. Positive hepatitis C virus RNA\n   3. Suspicion of drug-induced liver disease\n   4. Alcoholic liver disease\n   5. Autoimmune hepatitis\n   6. Wilson's disease\n   7. Hemochromatosis\n   8. Primary biliary cholangitis or primary sclerosing cholangitis\n   9. Known or suspected hepatocellular carcinoma\n4. Medications which cause liver disease or secondary hepatic steatosis (Tamoxifen, systemic corticosteroids, methotrexate, tetracycline, estrogens, valproic acid, and statin (registration is possible if statin is delivered in a consistent dosage within 12 weeks)\n5. Current or recent history (\\\u003C5 years) of significant alcohol intake (\\>30g of alcohol\u002F day or \\>210g\u002Fweek for men, \\>20g of alcohol\u002Fday or \\>140g\u002Fweek for women)\n6. Doctor diagnosed diabetes mellitus on insulin or sulfonylureas\n7. Severe medical comorbidities \\[ischemic heart disease, 3rd degree atrioventricular block, chronic obstructive pulmonary disease, severe hypertension (blood pressure \\>200\u002F120 mmHg)\\]\n8. Unstable weight (\\>5% change in the last 2 months) or participation in a weight-loss program within the past 12 weeks\n9. Sleep disorder (with a medical diagnosis) or individuals self-reporting sleep difficulties and poor sleep \\[average sleep less than 6 consecutive hours or patients who systematically experience sleep interruption for more than 2 times each night (waking up for toilet use is not to be considered sleep interruption)\\]\n10. Individuals with food allergies (or hypersensitivity to the fruits and vegetables that will be selected for the study)\n11. Systematic organic products consumers (defined as a self-reported usual consumption of more than 80% of their weekly fruits \\& vegetables being organic)\n12. Pregnant or trying to become pregnant or lactating women\n13. People not in position to communicate in Greek or English language\n14. Having metallic parts in the body.","70 Years",{"count":51,"type":20},150,"INTERVENTIONAL",[54],"NA","The goal of this clinical trial is to study the effect of a time-restricted eating (TRE) dietary pattern combined with a time of consumption restriction about the daily portions of fruits and vegetables in people diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD).\n\nThe protocol of the study is an intention to treat protocol. The main research questions are:\n\n1. Does compliance in a TRE dietary scheme (positively) affect changes in body weight and body fat mass in people diagnosed with MASLD?\n2. Does an additional time restriction on the consumption of fruits and vegetables within the \"light-window\" of the day affects the metabolism of food contaminants?\n\nParticipants will be asked to:\n\n1. Adhere to a TRE dietary pattern for 3 months. TRE consists of an 8-hour eating vs 16 hours fasting within the day. First meal of the day should not occur at least an hour after wake-up time and last meal of the day should occur not later than 2 hours before bed-time.\n2. Adhere to a further time restricted consumption of a \"5-a-day\" portions of fruits and vegetables between the \"light-window hours\" between 9am to 4pm.\n3. Visit the Nutrition \\& Dietetics Clinic once every month for anthropometric measurements (on 4 time points).\n4. Collect and deliver first morning urine samples (on 7 time points).\n5. Collect and deliver saliva samples at baseline and at the end of the trial (Saliva collection should occur every 4-hours for 48-hours including fasting collection at baseline and at the end of three months)\n\n5\\) Complete a compliance and lifestyle questionnaire questionnaire via telephone interview to the research team every 2 weeks.\n\n6\\) Share photos to the research team with the use of an application on time of actual fruit and vegetables consumption, 3-4 times per week throughout the study protocol.\n\nResearchers will compare the designed intervention package of this TRE with the Standard of Care (SoC) protocol (based on the international guidelines) that is currently used in daily practice for the management of MASLD.",[24,57,26,58,27],"MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","NAFLD - Non-Alcoholic Fatty Liver Disease",[60,61,62,63,64,65,24,66],"non alcoholic fatty liver disease (NAFLD)","chrononutrition","intermittent fasting","randomized controlled trial (RCT)","chronotoxicity","time restricted eating","Metabolic Dysfunction-Associated Steatotic Liver Disease","NOT_YET_RECRUITING","2025-11-18",{"date":70,"type":32},"2025-11-19",{"date":72,"type":20},"2026-01-05",{"date":74,"type":20},"2029-12-15",{"name":76,"class":39},"Cyprus University of Technology",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":16,"minAge":17,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100605901","is-there-a-relationship-between-uric-acid-level-and-liver-fibrosis-in-obese-patients-100605901","NCT07168551","Is There a Relationship Between Uric Acid Level and Liver Fibrosis in Obese Patients","Association of Hyperuricemia and Non Alcoholic Fatty Liver Disease and Liver Fibrosis Risk in Adult Obese Patients","Inclusion Criteria:\n\n1. Age: Adults (typically 18-65 years old)\n\n2 - Body Mass Index (BMI): Obese patients with a BMI ≥ 30 kg\u002Fm²\n\n3- Hyperuricemia : Elevated serum uric acid levels (typically \\> 7 mg\u002FdL for men and \\> 6 mg\u002FdL for women)\n\nExclusion Criteria:\n\n* excessive alcohol consumption ( \\> 20 gm \u002Fday in men and 10 in g \u002Fday in women )\n\n  2- use of steatogenic within the past 6 months\n\n  3- positive test for hepatitis B surface antigen and hepatitis B core antibody\n\n  4- Drug induced liver injury and autoimmune hepatitis\n\n  5 - cirrhosis and other causes of liver disease",true,"65 Years",{"count":87,"type":20},111,"1. Identifying the association between hyperuricemia and NAFLD can lead to early detection and prevention of liver fibrosis in adult obese patients.\n2. Understanding the relationship between hyperuricemia and NAFLD can inform targeted therapy, such as urate-lowering treatment, to potentially slow disease progression.\n\n3 - To examine the relationship between serum uric acid levels and liver fibrosis severity\\*: Assessing the correlation between serum uric acid levels and the severity of liver fibrosis in adult obese patients with NAFLD.\n\n4- To identify potential mechanisms underlying the association\\*: Exploring the potential mechanisms by which hyperuricemia may contribute to the development and progression of NAFLD and liver fibrosis in adult obese patients.",[90,27,91],"Hyperuricemia","Liver Fibrosis","2025-09-12",{"date":94,"type":32},"2025-09-15",{"date":96,"type":20},"2025-10-01",{"date":98,"type":20},"2026-12-01",{"name":100,"class":39},"Assiut University",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":84,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":52,"phases":111,"briefSummary":112,"conditions":113,"keywords":118,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100600119","the-impact-of-pectin-supplementation-on-systematic-inflammation-pathway-gut-microbiome-and-metabolic-health-in-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease-masld-100600119","NCT07093346","The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Randomised, Placebo-Controlled, Dietary Intervention Study","PEC-MASLD","Inclusion Criteria:\n\nInclusion criteria for the main study:\n\n* Patients with clinical diagnosis of MASLD (formerly termed non-alcoholic fatty liver disease (NAFLD)), having assessment suggesting that liver fat \\> 5% (e.g. histological evidence or\u002F and Transient Elastography using Controlled Attenuation Parameter (CAP)- FibroScan™ in the past month and\u002For liver imaging (such as ultrasound, computerized tomography (CT) or magnetic resonance imaging (MRI)).\n* Participants willing and able to give informed consent for participation in the study.\n* Participants aged ≥18 years who have a body mass index (BMI) between 18.5 and 39.9 kg\u002Fm2 and stable weight (weight gain or loss ≤ 3kg) for the past 3 months.\n* For diabetic participants: controlled blood glucose levels Haemoglobin A1C (HbA1c) \\\u003C7.0% (\\\u003C53 mmol\u002Fmol) \\[1\\].\n* Able to undergo CAP-FibroScan™.\n\nInclusion criteria for healthy participants who will have MRI scans:\n\n* Participants willing and able to give informed consent for participation in the study.\n* Participants aged ≥18 years.\n* participants with CAP\\\u003C250 kpa\\\u003C8kP by a FibroScan™ within the past 6 months.\n\nExclusion Criteria:\n\nExclusion criteria for the main study:\n\n* Have allergy toward soya, milk or chocolate.\n* Have allergy toward pectin.\n* Participants on vegan diet.\n* Have eating disorders or difficulties or gastrointestinal conditions e.g. malabsorptive conditions such as coeliac, Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD) or gastroparesis.\n* Have chronic malnutrition condition.\n* History of major surgery which potentially limits participation or completion of the study.\n* History of previous intestinal surgery known to affect food intake or digestive function, including bariatric surgery.\n* Use of antibiotics, antifungal medications, probiotics or prebiotics 90 days before the start of the study.\n* Are taking the following medications: immunosuppressants, amiodarone and\u002For perhexiline.\n* Are currently following or anticipated to commence a specialised commercially available weight loss diet and\u002For program or concomitant use of any weight loss medication or herbal weight loss products.\n* History of side effects towards probiotics or prebiotics.\n* History or current psychiatric illness.\n* History or current neurological condition (e.g. epilepsy).\n* Participants with other liver abnormalities.\n* Evidence of monogenic metabolism diseases such as Lysosomal acid lipase deficiency (LALD), Wilson disease, Hypobetalipoproteinemia, or inborn errors of metabolism.\n* Have had a weight change exceeding 3 kg within 3 months.\n* Uncontrolled diabetes, active malignancy, or chronic infections.\n* Having symptoms of active infection.\n* Excessive alcohol intake defined as self-reported intakes greater than 21 units per week in men, and 14 units per week in women.\n* Participants who are pregnant, breast feeding or actively planning pregnancy will be excluded from the study.\n* Participation in any other trial in the last 3 months.\n\nExclusion criteria for healthy volunteers MRI scans and patients optional MRI scans:\n\n* Contraindications for MRI scanning: having pacemakers, defibrillators, neurostimulators, prohibited medical implants, and foreign bodies (e.g. bullets, shrapnel, metal slivers), history of metallic foreign body in eye(s) and penetrating eye injury that could present a risk during an MRI scan.\n* Difficulty breathing or inability to lie flat, as well as conditions that could worsen under stress (such as anxiety or panic disorders, claustrophobia, uncontrolled hypertension, or seizure disorders) severe enough to prevent undergoing an MRI.",{"count":110,"type":20},45,[54],"The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce systemic inflammation and improve gut microbiota composition in adults recently diagnosed with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The main question it aims to answer is:\n\n-How does dietary Low-methoxy (LM) pectin supplementation affect systematic inflammation pathways such as those mediated by gut microbiota composition and what are the impacts on general metabolic indicators in individuals with MASLD?\n\nResearchers will compare a group taking 15g of LM-pectin with 10g of cocoa powder to a placebo group receiving 10g of placebo with 10g of cocoa powder to see if LM-pectin has measurable effects on inflammation and gut microbiota.\n\nParticipants will:\n\n* Take a daily supplement for 6 weeks: either 15g of LM-pectin with 10g of cocoa powder (intervention), or 10g of placebo with 10g of cocoa powder (control)\n* Provide stool and fasting blood samples before and after the intervention\n* Undergo anthropometric measurements (weight, height, waist\u002Fhip ratio, and blood pressure)\n* Complete a case report form (CRF) including demographics and health\u002Fmedical history\n* Undergo a FibroScan™ to assess liver health\n* (Optional) Participate in MRI scans to evaluate gut permeability",[114,115,57,24,26,66,27,116,58,117],"Nonalcoholic Fatty Liver Disease","Nonalcoholic Fatty Liver Disease (NAFLD)","NAFLD (Non-alcoholic Fatty Liver Disease)","NAFLD - Nonalcoholic Fatty Liver Disease",[119,120,24,26,114,121,122,123,124,125,66],"LM pectin","pectin","Systemic Inflammatory Response","Dietary Fiber","Dietary Fibre","Diet","gut microbiota","2025-07-22",{"date":128,"type":32},"2025-07-30",{"date":130,"type":32},"2025-06-10",{"date":132,"type":20},"2027-03-31",{"name":134,"class":39},"University of Nottingham",3,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":145,"conditions":146,"keywords":152,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":40},"100598351","digital-early-warning-system-for-acute-lung-injury-in-liver-surgery-100598351","NCT07070362","Digital Early Warning System for Acute Lung Injury in Liver Surgery","The Construction of a Digital Intelligence Early Warning System for the Whole Process of Acute Lung Injury in Liver Surgery Based on Cardiopulmonary Interaction Characteristics","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Undergoing major liver surgery (including two-segment or more hepatectomy, liver transplantation, etc.)\n* Voluntary participation with signed informed consent",{"count":144,"type":20},4000,"This study focuses on developing an explainable machine learning model based on cardiopulmonary interaction characteristics to achieve early prediction of acute lung injury (ALI) in patients undergoing major liver surgery. The research will establish a digital early-warning system for ALI to provide support for clinical diagnosis and treatment decisions, thereby reducing the incidence and fatality rate of ALI.",[147,148,149,24,150,27,151],"Acute Lung Injury(ALI)","Liver Cirrhosis","ARDS, Human","MASLD\u002FMASH (Metabolic Dysfunction-Associated Steatotic Liver Disease \u002F Metabolic Dysfunction-Associated Steatohepatitis)","Liver Cancer, Adult",[153,154,155,156,157],"Digital Intelligence","Acute Lung Injury","PPCs","Liver Surgery","Cardiopulmonary Interaction;","2025-07-08",{"date":160,"type":32},"2025-07-17",{"date":162,"type":32},"2024-11-01",{"date":164,"type":20},"2027-11-30",{"name":166,"class":39},"Beijing Tsinghua Chang Gung Hospital",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":84,"sex":16,"minAge":17,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":52,"phases":176,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":40},"100587738","integrating-metabolic-and-vascular-sensors-to-monitor-cardiometabolic-disorders-after-nutrition-interventions-100587738","NCT06932289","Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions","Inclusion Criteria:\n\n* United States Veterans\n* Male or female, age 18-55 years at the time of signing informed consent.\n* at least 2 of the following: waist circumference \\> 40\" for men and 35\" for women, FBS \\>100 mg\u002Fdl, triglycerides \\> 150 but \\\u003C 500 mg\u002FdL, HDL \\\u003C 40 mg\u002FdL, Pre- hypertension or hypertension (BP\\>120\u002F80 mmHg but \\\u003C150\u002F90 mmHg)\n\nExclusion Criteria:\n\n* History of diabetes require medications\n* History of alcohol intake ≥ 20g\u002Fday\n* History of cirrhosis\n* Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of \\\u003C30 mL\u002Fmin\u002F1.73 m2\n* History of thyroid disease, but not taking medication or medication dosage changed one or more times over last 6 months. History of thyroid disease and on a stable dose of prescription medication for 6 months or longer is acceptable.\n* Any unstable medical conditions or terminal diagnosis.\n* Any participant who is unwilling to sign an informed consent form will not be admitted into the study.","55 Years",{"count":175,"type":20},54,[54],"It is a 12-week study. The participants will follow three different diets, and during each diet period, and the participants will wear our device, and blood samples will be collected.",[27],[26,180,181],"metabolic responses","mixed meal challenge","2025-04-09",{"date":184,"type":32},"2025-04-17",{"date":186,"type":20},"2025-05-01",{"date":188,"type":20},"2029-05-01",{"name":190,"class":191},"VA Greater Los Angeles Healthcare System","FED",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":85,"enrollmentInfo":198,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":200,"conditions":201,"keywords":205,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":4},"100572916","efficacy-of-sodium-glucose-cotransporter-2-inhibitors-on-non-alcoholic-fatty-liver-disease-100572916","NCT06739486","Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease","Inclusion Criteria:\n\n* age \\>18 years\n* both sex\n\nExclusion Criteria:\n\n* alcohol drinker\n* any cause of liver affection (hepatitis, autoimmune…etc)\n* patients with kidney function affection",{"count":199,"type":20},100,"evaluate the effectiveness of sodium-glucose cotransporter-2 (SGLT.2) inhibitors in improving hepatic steatosis and hepatic fibrosis using imaging biomarkers and histopathology in patients with non-alcoholic fatty liver disease",[202,203,204,27],"Non Alcholic Fatty Liver Disease","Hepatic Steatosis","Hepatic Fibrosis",[26,206,207,208,209,210],"Non alcoholic fatty liver disease","Hepatic steatosis","Hepatic fibrosis","Na glucose cotransporter 2 inhibitors","SGLT-2 inhibitors","2024-12-17",{"date":213,"type":32},"2024-12-18",{"date":215,"type":20},"2024-12-20",{"date":217,"type":20},"2025-12-20",{"name":100,"class":39}]